Expression and biological-clinical significance of hTR, hTERT and CKS2 in washing fluids of patients with bladder cancer by Mezzasoma, Letizia et al.
RESEARCH ARTICLE Open Access
Expression and biological-clinical significance of
hTR, hTERT and CKS2 in washing fluids of patients
with bladder cancer
Letizia Mezzasoma
1*, Cinzia Antognelli
1, Chiara Del Buono
1, Fabrizio Stracci
2, Emanuele Cottini
3,
Giovanni Cochetti
3, Vincenzo N Talesa
1, Ettore Mearini
3
Abstract
Background: at present, pathogenesis of bladder cancer (BC) has not been fully elucidated. Aim of this study is to
investigate the role of human telomerase RNA (hTR), human telomerase reverse transcriptase (hTERT) and CDC28
protein kinase regulatory subunit 2 (CKS2) in bladder carcinogenesis and their possible clinical significance;
Methods: the transcript levels of hTR, hTERT and CKS2 were quantified by Real time reverse transcriptase chain
reaction in exfoliated cells from bladder washings of 36 patients with BC and 58 controls. The statistical
significance of differences between BC bearing patients and control groups, in the general as well as in the
stratified analysis (superficial or invasive BC), was assessed by Student’s t test. Non parametric Receiver Operating
Characteristics analysis (ROC) was performed to ascertain the accuracy of study variables to discriminate between
BC and controls. The clinical value of concomitant examination of hTR, hTERT and CKS2 was evaluated by logistic
regression analysis;
Results: a significant decrease in hTR and a significant increase in hTERT or CKS2 gene expression were found
between BC bearing patients and controls, as well as in the subgroups analysis. The area under the curve (AUC)
indicated an average discrimination power for the three genes, both in the general and subgroups analysis, when
singularly considered. The ability to significantly discriminate between superficial and invasive BC was observed
only for hTR transcript levels. A combined model including hTR and CKS2 was the best one in BC diagnosis;
Conclusions: our results, obtained from a sample set particularly rich of exfoliated cells, provide further molecular
evidence on the involvement of hTR, hTERT and CKS2 gene expression in BC carcinogenesis. In particular, while
hTERT and CKS2 gene expression seems to have a major involvement in the early stages of the disease, hTR gene
expression, seems to be more involved in progression. In addition, our findings suggest that the studied genes
have a clinical role in discriminating between BC and controls in the general as well as in the stratified analysis,
when singularly considered. A combined model improved over the single marker BC diagnosis.
Background
Bladder cancer (BC) is one of the most common world-
wide malignancies. In the Western world it is the fourth
most common malignancy among men, following pros-
tate, lung and colon cancers and represents the second
most common cause of death among genitourinary
tumors [1]. BC consists of a heterogeneous group of
tumors that display a broad clinical spectrum ranging
from superficial and well differentiated lesions to inva-
sive and poorly differentiated cancers, which represents
a key problem in its management. While there is a
wealth of molecular information on BC, it is still not
possible to derive a clear model for the molecular
pathogenesis of all these tumors [2]. An enhanced
understanding of the molecular biology of BC, could
provide new insight into BC pathogenesis.
Telomerase is a specialized ribonucleoprotein complex
including an RNA component, human telomerase RNA
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scriptase (hTERT), which stabilizes the telomeres of lin-
ear chromosomes [3,4]. Although telomerase activity is
present during human embryonic development, its
expression and activity are repressed in most normal
adult tissues. In contrast, most human tumours display
high levels of telomerase [4-6]. Such an expression in
cancer cells might be a necessary and essential step for
tumor development and progression [6]. On the other
hand, other findings indicate that telomerase expression
might not be an obligate requirement in some settings
for initial tumor growth, but play an important role for
long-term maintenance [7,8]. Moreover, other observa-
tions suggest an additional role for telomerase during
multistep oncogenesis [9]. In particular, further develop-
m e n t si n d i c a t et h a tt e l o m e r eb i o l o g yk n o w l e d g es t i l l
remains incomplete, and implicate additional complexity
in the relationship among telomeres, telomerase and
cancer [9].
The subunit 2 of the cyclin kinase Cdc28/CDC2
(CKS2) is an essential component for cell cycle control,
involved in cell cycle progression from G1 to S and
from G2 to M [10]. It has also been shown that CKS2 is
essential for the first metaphase/anaphase transition of
mammalian meiosis [11]. Accumulating evidence shows
an extensive expression of CKS2 in malignant tumors of
different tissues, including meningioma [12] as well as
prostate [13], cervical [14], gastric [15], colon and liver
[16] carcinomas.
The role of telomerase or CKS2 in carcinogenesis, has
made these molecules of growing interest in BC research.
Regarding the former, studies have pointed out that telo-
merase activity as well as the mRNA expression levels of
its subunits are associated with malignancy in many BC
tumor histotypes [17-22]. In particular, the expression of
hTERT and hTR mRNA, both in tissues [22] and in
voided urine samples [23], seems to correlate positively
with tumor stage and grade, even if these data have not,
as yet, been confirmed [24]. Hence, the biological rele-
vance of telomerase remains to be fully elucidated and
needs further investigation. Recently, CKS2 has been also
studied in BC where it was significantly up-regulated, not
only when BC was compared to normal bladder tissue,
but also when invasive was compared to superficial BC
[25]. The difference in the CKS2 expression level between
invasive BC and the normal bladder tissue was greater
than between superficial BC and the normal bladder
tissue, thus suggesting that CKS2 expression may influ-
ence BC progression via cell cycle advancement [25].
A tp r e s e n t ,t h i si st h eo n l yw o r kt od e s c r i b eap o s s i b l e
role of CKS2 in this neoplasia.
The aim of this study was to investigate the biological
role of hTR, hTERT and CKS2 in BC development and
progression. Therefore, in the first part of the present
study, we quantified the transcript levels of these mole-
cules in samples particularly rich of exfoliated cells
(bladder washings) from patients with or without BC.
Since we observed significant changes in the expres-
sion levels of the three considered genes between BC
bearing patients and controls, we also decided to evalu-
ate their possible role as molecular markers of BC diag-
nosis and progression.
Methods
Patients database
The present project was developed at the Cell and
Molecular Biology Laboratory of the University of Peru-
gia together with the Urology Service of the University
Hospital. The study protocol followed the guidelines of
our local ethics committee and the investigation was
conducted with the ethical requirements defined in the
Helsinki Declaration. All patients gave their informed
consent to participate in the study. The study included
94 consecutive patients undergoing flexible cystoscopy
either for bladder cancer (BC) diagnosis or for other
clinical indications. The subjects were classified into two
age and sex matched groups. The first one included 36
patients (32 male, 4 female) with a histopathological
diagnosis of BC. All these patients were at the first diag-
nosis of BC. Mean age ± SD of BC group was 68.8 ±
10.8 years (range 48 to 87). The second group (controls)
included 58 patients (49 male, 9 female) with a mean
age ± SD of 69.9 ± 10.6 years (range 41 to 86). Tumor
stage was determined using TNM (Tumor lymph Nodes
and Metastasis) and grading according to the World
Health Organization (WHO 2004) guide lines. All
tumors were classified as: 72.2% (26/36) superficial low
grade [pTa (n = 24), pT1 (n = 2)], 27.8% (10/36) muscle
invasive high grade [pT2-4 (n = 10)]. Among controls
24.1% (14/58) were patients with no history of malig-
nancy (with hematuria/irritative symptoms) and 75.9%
(44/58) were patients enrolled in a 2 years follow up
from the time of BC diagnosis. At the time of sampling,
all controls were BC free.
Collection of samples
60 ml of washing fluids were collected during flexible
cystoscopy and immediately cooled on ice. Upon centri-
fugation at 4°C and 1200 rpm for 10 min, the sediments
containing exfoliated cells were washed twice by suspen-
sion in ice-cold phosphate-buffered saline (PBS) and
further centrifugation at 4°C and 1200 rpm for 10 min
as well. Sediments thus obtained were snap frozen in
TRIzol Reagent (Invitrogen, Milan, Italy), and stored at
-70°C until subsequent use. We used bladder washes for
detection of hTERT, hTR and CKS2 gene expression,
because the number of exfoliated cells in these fluids
has been shown to be higher than in voided urine [26].
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tion of urothelial malignancy has been shown to be bet-
ter than voided urine [27]. Besides, cytology from
bladder washing has been shown to be better than that
from voided urine in the detection of bladder cancer
[28,29].
RNA isolation and cDNA synthesis
Total cellular RNA was isolated from the sediments using
TRIzol Reagent (Invitrogen, Milan, Italy) according to the
manufacturer’s instructions. The quality and quantity of
RNA was established spectrophotometrically by absor-
bance readings at 260 and 280 nm. Total RNA (1 μg) was
reverse transcribed using the RevertAid™HM i n u sF i r s t
Strand cDNA Synthesis Kit (Fermentas, Hanover, MD)
and random primers System (Invitrogen, Milan, Italy).
Following cDNA synthesis, the resulting mixture was
heated at 95°C for 5 min before storage at -20°C.
Quantitative Real Time PCR analysis
Beacon Designer 4 software (Stratagene, La Jolla, CA)
was used for the design of suitable combinations, either
of TaqMan primers and probes or SYBR Green primers.
The sequences of oligonucleotide primers and probes
used for real time PCR were as follows: human telomer-
ase RNA (hTR): 5’-cgccttccaccgttcattc-3’ (sense, 400 nM),
5’-gctgacagagcccaactc-3’ (antisense, 400 nM), 5’-FAM-
agctgctggcccgttcgccc-TAMRA-3’ (TaqMan Probe, 200
nM); human telomerase reverse transcriptase (hTERT):
5’-cgagagcagacaccagcag-3’(sense, 400 nM), 5’-cggacact-
cagccttcagc-3’(antisense, 400 nM); CDC28 protein kinase
regulatory subunit 2 (CKS2): 5’-catgagccagaaccacatattc-
3’(sense, 400 nM), 5’-cagctcatgcacaggtatgg-3’(antisense,
400 nM); b actin:5 ’-cactcttccagccttccttcc-3’(sense, 600
nM), 5’-acagcactgtgttggcgtac-3’(antisense, 600 nM),
5’-Cy5-tgcggatgtccacgtcacacttca-BHQ2-3’(TaqMan
Probe, 200 nM). Standards were prepared by classical
PCR from cDNA obtained from LNCaP cell line (ATCC
# CRL-1740) for the concerned target mRNAs. PCR pro-
ducts were purified from agarose gel using the Qiaquick
DNA Fragment Purification kit (Qiagen, Milan, Italy),
according to the manufacturer’s instructions. Serial dilu-
tions of each standard were subsequently prepared to
obtain, following real time PCR amplification, the refer-
ence standard curve to extrapolate quantitative informa-
tion for cDNA targets of unknown concentrations.
Detection of specific mRNAs expression was carried out
by either quantitative Real Time TaqMan or SYBR Green
PCR analysis on a MX3005P Real-Time PCR System
(Stratagene, La Jolla, CA). The amplification reactions
were performed in quadruplicate for each sample. In our
experiments, the calibration curves consisted of at least 6
points, and each concentration was run in triplicate.
Only calibration curves with an R square (R
2)v a l u eo f
0.985-0.995 and efficiency between 90% and 100% were
considered. Each PCR run consisted of the specific 6
point calibration curve, a no template control, and the
specimen cDNAs.
As to CKS2, hTR, hTERT, and b actin (the housekeep-
ing gene used for normalization), PCR reactions were
performed in a total volume of 25 μl, containing 250 ng
of cDNA for CKS2 and 500 ng for hTR and hTERT,1 ×
Brilliant QPCR master mix or Brilliant SYBR Green
QPCR Master mix (Stratagene, La Jolla, CA), plus a con-
centration of specific primers and probes, as above
described. The PCR conditions were: CKS2: 1 cycle at
95°C for 10 min, 45 cycles at 95°C for 15 s, 63°C for 1
min; hTR: 1 cycle at 95°C for 10 min, 45 cycles at 95°C
f o r3 0s ,6 1 ° Cf o r1m i n ;hTERT: 1 cycle at 95°C for 10
min, 45 cycles at 95°C for 30 s, 64°C for 1 min, 72°C for
30 s; b actin: 1 cycle at 95°C for 10 min, 45 cycles at
95°C for 30 s, 64°C for 1 min, 72°C for 30 s.
The level of b actin expression was measured in all
samples to normalize hTR, hTERT and CKS2 expression
for sample-to-sample differences in total volume of
bladder washings, numbers of exfoliated cells, RNA
input, RNA quality, and reverse transcription efficiency.
Statistical Analysis
The results concerning the groups of patients with or
without BC were compared by c
2 test for categorical
variables. The statistical significance of differences
between BC patients and control groups was assessed by
Student’s t test. Differences were considered significant
when P < 0.05. Most analyses were carried out using ln
transformed variables to improve normality of distribu-
tion and data interpretability.
Nonparametric receiver operating characteristic analy-
sis (ROC) was performed to assess the accuracy of study
variables to discriminate between BC patients and con-
trols [30,31]. Logistic regression was used to assess the
independent predictive ability of study variables. The
individual probabilities of a positive outcome, based on
the model coefficients, were used to calculate the AUCs
after logistic regression.
Due to the asymmetry and large variability of the
observed urinary concentrations, logistic regression was
performed on ln transformed data. The logistic model
was calculated in the presence of only 5% of missing
data, thus not leading to biased results. A multinomial
logistic model was fitted to study data for the following
three categories: controls (reference), superficial bladder
cancer (SBC) and invasive bladder cancer (IBC). Stata
10 SE was used to perform statistical analyses (Stata
Corp. 2007. Stata Statistical Software: Release 10.
College Station, TX: StataCorp LP).
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Quantification of markers transcripts
Table 1 shows the descriptives t a t i s t i c so ft r a n s c r i p t
levels concerning human telomerase RNA (hTR), human
telomerase reverse transcriptase (hTERT)a n dC D C 2 8
protein kinase regulatory subunit 2 (CKS2) in exfoliated
cells from bladder washings carried out in bladder can-
cer (BC) patients and controls. Real time PCR analysis
of the three studied genes revealed highly significant dif-
ferences between BC and controls. In particular, hTR
showed a significant 4.4 fold decrease compared to con-
trols (Figure 1). Conversely, hTERT and CKS2 showed a
significant 11.4 fold and 5.6 fold increase compared to
controls, respectively (Figure 1).
In the attempt to evaluate a possible role of the stu-
died genes in the development and progression of blad-
der tumors, we compared the transcript levels of hTR,
hTERT and CKS2 in exfoliated cells from superficial low
grade (pTa, pT1) or muscle invasive high grade (pT2-4)
BC and controls (Table 2). All analyses comparing sub-
groups by stage are exploratory, because of the small
number of study cases. We found significant differences
in the expression levels of the three considered genes
among the control, superficial and invasive groups. In
particular, regarding hTR, a significant decrement was
observed in superficial BC (SBC), becoming more evi-
dent in invasive BC (IBC) (Figure 2). Conversely, hTERT
and CKS2 showed almost the same up regulation both
in SBC and IBC (Figure 2).
hTR, hTERT and CKS2 as molecular markers of bladder
cancer
In the attempt to evaluate the ability of each considered
molecule in discriminating between bladder cancer (BC)
and controls, we performed Receiver Operating Charac-
teristic (ROC) curves for each study variable. The area
under the curve (AUC) was 0.72 (95% CI: 0.62-0.83) for
hTR, 0.76 (95% CI: 0.65-0.87) for hTERT and 0.67 (95%
CI: 0.55-0.80) for CKS2, thus indicating an average dis-
crimination power between BC and controls for all
these tests, when singularly considered (Figure 3).
In order to establish if a combination of markers
could enhance the diagnostic relevance of the assay, we
evaluated, by using a logistic regression model, whether
the whole of all 3 markers, combinations of 2 of them,
or the use of single ones were most useful. A model
including hTR and CKS2 was the best one in BC diag-
nosis (Table 3) and showed a higher clinical perfor-
m a n c ei nc o m p a r i s o nt oe a c hs i n g l et e s t e dm a r k e r
(AUChTR = 0.71, 95% CI: 0.60-0.82; AUChTERT = 0.74,
95% CI: 0.625-0.86; AUCCKS2 = 0.66, 95% CI: 0.53-0.79;
AUChTR/CKS2 = 0.87, 95% CI: 0.78-0.96) (Figure 4).
In the attempt to evaluate the ability of each consid-
ered molecule in discriminating between SBC or IBC
and controls, we performed ROC curves for each study
variable. The AUCs values were 0.67 (95% CI: 0.56-0.77)
for hTR, 0.75 (95% CI: 0.63-0.84) for hTERT and 0.65
(95% CI: 0.54-0.76) for CKS2. Such results pointed out
an average discrimination power between controls and
superficial forms for these tests, when singularly consid-
ered. The same analysis was performed for invasive
forms. The AUCs values were 0.88 (95% CI: 0.78-0.95)
for hTR, 0.78 (95% CI: 0.65-0.88) for hTERT and 0.72
(95% CI: 0.60-0.82) for CKS2. Finally, the ability to sig-
nificantly discriminate between superficial and invasive
BC was evaluated only for hTR transcript level (AUC:
0.78, 95% CI: 0.60-0.90, P = 0.0005). Therefore, all the
three studied molecules appear to be suitable in discri-
minating superficial or invasive BC forms from controls.
In addition, hTERT was the best one in discriminating
BC superficial forms, while hTR was the best one in dis-
criminating BC invasive forms.
To explore if the use of more predictors would be able
to discriminate also between controls and SBC or IBC, a
multinomial logistic model was employed. The hTR/
CKS2 combined model showed an improved discrimina-
tion between controls and SBC or IBC with respect to
each marker alone (Table 4).
Discussion
Bladder tumors show widely differing histopathology
and clinical behavior. During the past 10 years, evidence
has accrued on molecular pathways of bladder cancer
(BC). However, molecular mechanisms of BC develop-
ment and progression are not fully understood.
Our study characterizes the expression levels of three
different genes associated with carcinogenesis: human
telomerase RNA (hTR), human telomerase reverse
Table 1 Mean (± SE), 95% Confidence Interval (CI), median values for main study variables
CB C
Variable Mean (± SE) 95% CI Median Mean (± SE) 95% CI Median
hTR 3.9 × 10
-3 (±1.3 × 10
-3) 1.3 × 10
-3 -6.5 × 10
-3 7.0 × 10
-4 8.9 × 10
-4 (±4.2 × 10
-4) 3.5 × 10
-5 -1.7 × 10
-3 1.2 × 10
-4
hTERT 4.2 × 10
-5 (±8.5 × 10
-6) 2.4 × 10
-5 -5.9 × 10
-5 2.0 × 10
-5 4.8 × 10
-4 (±1.5 × 10
-4) 1.7 × 10
-4 -7.8 × 10
-4 1.2 × 10
-4
CKS2 6.1 × 10
-5 (±9.2 × 10
-6) 4.2 × 10
-5 -7.9 × 10
-5 4.8 × 10
-5 3.4 × 10
-4 (±1.0 × 10
-4) 1.3 × 10
-4 -5.5 × 10
-4 8.4 × 10
-5
C: Controls; BC: Bladder Cancer; hTR: human Telomerase RNA; hTERT: human Telomerase Reverse Transcriptase; CKS2: CDC28 protein kinase regulatory subunit 2;
CI: Confidence Interval; SE: Standard Error.
Mezzasoma et al. BMC Urology 2010, 10:17
http://www.biomedcentral.com/1471-2490/10/17
Page 4 of 10transcriptase (hTERT) and CDC28 protein kinase regu-
latory subunit 2 (CKS2) in BC patients and controls.
The evaluation was made in sediments from bladder
washings, samples particularly rich of exfoliated
tumor cells [26]. The choice of using bladder
washings is related to their usefulness and sensitivity
in detecting urothelial malignancy, as it was previously
shown [27,28].
Our results point out a significant difference in the
transcript levels of hTR, hTERT and CKS2 between BC
and controls. In particular, when BC group was com-
pared to controls, the former clearly showed a signifi-
cant 4.4 fold decrease in hTR expression level. Such a
result could be ascribed to specific regulation mechan-
isms at transcriptional level. In fact, transcriptional regu-
lation is emerging as the main action controlling hTR
gene expression [4]. Multiple mechanisms regulate the
hTR promoter in vivo [32] and a number of transcrip-
tion factors have been implicated. In particular, in blad-
der cancer cells, a role for MDM2 in hTR promoter
regulation, has been recently demonstrated [33]. MDM2
associates with the hTR promoter and negatively regu-
lates its activity [33], likely interfering with more than
one transcriptional regulator in a dominant fashion [4].
The decrement in hTR expression, observed in our
study, suggest its involvement in BC carcinogenesis.
Until the present, studies in the literature described an
increased expression of hTR in cancer patients with
respect to healthy individuals [22,23]. However, a peer
comparison with such studies is quite difficult to inter-
pret. In fact, to our knowledge, they refer to the evalua-
tion of hTR mRNA levels in urine samples and the only
study evaluating the expression of this molecule in
washing fluids is not methodologically comparable [27].
Conversely, hTERT expression levels showed an 11.4
fold increment in BC group compared to controls, sug-
gesting that its up regulation may have an important
role in BC carcinogenesis. The observed hTERT over
expression, could reflect the necessity in producing high
levels of proteins required for its biological function.
In fact, a significant association of telomerase
activity with hTERT expression has been already
Figure 1 Boxplots of mRNA expression levels of human Telomerase RNA (hTR), human Telomerase Reverse Transcriptase (hTERT) and
CDC28 protein kinase regulatory subunit 2 (CKS2), measured by real time PCR in exfoliated cells from bladder washings of controls
(C) and bladder cancer (BC) patients. The median values are depicted as solid lines.
Mezzasoma et al. BMC Urology 2010, 10:17
http://www.biomedcentral.com/1471-2490/10/17
Page 5 of 10previously shown [26,34]. Such a higher expression in
bladder washing fluids is in agreement with other pre-
vious findings [22-24,26,34-38].
With respect to CKS2, we observed a significant 5.6
fold up regulation in BC patients compared to controls,
suggesting that aberrantly expressed CKS2 may contri-
bute to BC initiation. Such a higher expression in blad-
der washing fluids is in agreement with the only report
describing that CKS2 expression is strongly correlated
with BC tumorigenesis [25].
Previous studies have shown that overexpression of
cyclins D1 and E is associated with high levels of telo-
merase activity [39] and that CDK overexpression is
required for telomerase activity in human and mouse
cancer cells [40]. Therefore, the parallel overexpression
of hTERT and CKS2, observed in our study, could sug-
gest a similar correlation also in BC and their involve-
ment in a common regulatory pathway.
We then evaluated the mRNA expression level of hTR,
hTERT and CKS2 in superficial and invasive BC
compared to controls. With regard to hTR,as t r o n g
down regulation correlating with BC progression was
observed, suggesting a possible role in the evolution of
the disease.
Conversely, hTERT and CKS2 transcript levels were
significantly up regulated in superficial forms, remaining
almost unchanged in the invasive ones, thus suggesting
a possible involvement of both of them in the early
events during tumor development. There have been sev-
eral attempts to correlate hTERT expression with BC
staging and histological grading often with rather con-
flicting results [22] or with results that have not, as yet,
been confirmed [21]. The present study, provides further
evidence supporting that hTERT mRNA expression is
not related to tumor stage.
Regarding CKS2, the only report on this subject corre-
lated CKS2 expression at tissue level, with tumor stage
[25]. The discrepancy between this study and ours may
be due to the different analyzed specimen. In fact, the
results emerging from tissue analysis, are not always
paralleled by the same significance in other samples.
Although the field of tumor markers in BC is rapidly
evolving no ideal marker currently exists. Among the
innovative methods of detection, the employ of molecu-
lar markers is promising. Molecular assays usually pro-
duce more qualitative (categorical) results with higher
sensitivity and reproducibility than the continuous data
typically produced by biochemical assays [41,42].
Since we observed significant changes in the expres-
sion levels of the three considered genes between BC
and controls, we then evaluated their possible role as
molecular markers of BC diagnosis and progression.
Calculating the Area Under the Receiver Operating
Characteristic (ROC) curve (AUC), we assessed the
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Page 6 of 10Figure 2 Boxplots of mRNA expression levels of human Telomerase RNA (hTR), human Telomerase Reverse Transcriptase (hTERT) and
CDC28 protein kinase regulatory subunit 2 (CKS2), measured by real time PCR in exfoliated cells from bladder washings of controls
(C) and superficial bladder cancer (SBC) and invasive bladder cancer (IBC) patients. The median values are depicted as solid lines.
Figure 3 ROC curves and AUCs for human Telomerase RNA (hTR), human Telomerase Reverse Transcriptase (hTERT) and CDC28
protein kinase regulatory subunit 2 (CKS2).
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Page 7 of 10discriminative ability of the transcript level concerning
hTR, hTERT and CKS2 between BC and controls, when
singularly considered (ROC areas ranging between 0.67-
0.76). Subgroup analysis of the disease revealed that
hTR, hTERT and CKS2 were able to discriminate
between controls and superficial or invasive BC (AUCs
ranging from 0.65 to 0.88).
Finally, our results suggest that a panel of markers,
evaluated through the transcription of their genes, can
be more useful than a single test for the diagnosis of
BC. In particular, the combination of transcript levels of
both hTR and CKS2 genes in the sediments of bladder
washings, improves, over the single biomarker, BC
diagnosis (AUC hTR/CKS2 0.87 vs AUCs ranging from
Table 3 Logistic regression model for BC diagnosis.
Predictors OR P 95% CI
ln(hTR) 0.43 0.0001 0.30-0.63
ln(CKS2) 4.2 0.0001 2.13-8.30
AUCROC 0.87 0.78-0.96
BC: Bladder Cancer; hTR: human Telomerase RNA; CKS2: CDC28 protein kinase
regulatory subunit 2; OR: Odds Ratio; 95% Confidence Interval; AUC: Area
Under Curve; ROC: Receiver Operating Characteristic curve.
Figure 4 ROC curves derived from the model including human Telomerase RNA (hTR) and CDC28 protein kinase regulatory subunit 2
(CKS2) compared with hTR, CKS2 and human Telomerase Reverse Transcriptase (hTERT) ROC curves.
Table 4 Multinomial logistic model comparing controls
(C, reference) with superficial (SBC) and invasive bladder
cancer (IBC)
Predictors OR P 95% CI
C Ref.
SBC
ln(hTR) 0.50 0.0001 0.34-0.74
ln(CKS2) 3.9 0.0001 1.95-7.76
IBC
ln(hTR) 0.10 0.001 0.03-0.41
ln(CKS2) 16.7 0.001 3.19-87.2
AUCROC[C-SBC] 0.82 0.71-0.94
AUCROC[C-IBC] 0.98 0.95-1.0
hTR: human Telomerase RNA; CKS2: CDC28 protein kinase regulatory subunit
2; OR: Odds Ratio; 95% Confidence Interval; AUC: Area Under Curve; ROC:
Receiver Operating Characteristic curve.
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Page 8 of 100.66 to 0.74). Hence, we agree with the general concept
that for the diagnosis of heterogeneous diseases such as
BC, the employment of a combined analysis of several
markers seems to be the most promising approach [43].
With regard to subgroups analysis, the hTR/CKS2
combined model turned out to be useful in discriminat-
ing both superficial or invasive forms, compared to con-
trol. However, given the small number of invasive
cancers, this may be regarded as an exploratory analysis.
Conclusions
Our results, obtained from a sample set particularly rich
of exfoliated cells, provide further molecular evidence
on the involvement of hTR, hTERT and CKS2 gene
expression in bladder cancer (BC) carcinogenesis.
In particular, while hTERT and CKS2 gene expression
seems to have a major involvement in the early patho-
genesis of the disease, hTR gene expression seems to be
more associated with BC progression. Furthermore, the
investigation of a possible clinical role of the three con-
sidered genes points out the ability to generally discrimi-
nate between control and BC, or superficial or invasive
BC, when singularly considered. Finally, our results sug-
gest that a panel of markers, evaluated through the tran-
scription of their genes, can be more useful than a single
test for diagnosis of BC. In particular, the combination
of bladder washings transcript levels of both hTR and
CKS2 genes improves, over the single biomarker, BC
diagnosis. Further investigation will be necessary to con-
firm the role of hTR in BC progression.
Therefore, it could be of particular interest to extend
the study to a larger population and to confirm these
results in urine, to provide a useful non-invasive tool in
detection and clinical evaluation of BC.
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